1 / 17

Vulvodynia Research Studies: National Institutes of Health

Vulvodynia Research Studies: National Institutes of Health. Vulvodynia: Clinical Study. UMDNJ- Robert Wood Johnson Medical School Women’s Health Institute. Vulvodynia clinical study: Research Questions.

jvogl
Download Presentation

Vulvodynia Research Studies: National Institutes of Health

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Vulvodynia Research Studies: National Institutes of Health

  2. Vulvodynia:Clinical Study UMDNJ- Robert Wood Johnson Medical School Women’s Health Institute

  3. Vulvodynia clinical study: Research Questions • Characterize demographics and epidemiologic aspects of vulvodynia • Examine efficacy of popularly prescribed interventions for vulvodynia in a rigorously controlled environment

  4. Vulvodynia clinical study:Current Research Design • Phase 1: Survey study to evaluate chronic gynecologic pain in a central New Jersey population of women • Phase 2: Diet intervention of low oxalate vs. low fat/high fiber diet • Phase 3: Three-arm treatment intervention study: • Self management Intervention • Tricyclic antidepressant (TCA) • Combination TCA and topical steroid • Phase 4: National survey to evaluate chronic gynecologic pain • Phase 5: International Meeting for Data Dissemination

  5. Vulvodynia Clinical Study: Phase 1 Data (Central New Jersey Survey) • 1794 questionnaires mailed • 37% response rate • 21% positive for chronic gynecologic pain • 13.5% positive for vulvodynia-type pain

  6. Vulvodynia Clinical Study:Phase 1: Preliminary Data Vulvodynia responders: • 49.6 years (average age) • 86.4% of responders-white • OCP use not associated with increased risk

  7. Vulvodynia Clinical Study:Subject Inclusion Criteria for Phases 2 and 3 • Ages 18 to 80 years • Vulvar pain present for at least 6 months • Vulvar symptoms of pain, itching, burning and/or tenderness of the vulva • No active vulvovaginal infection • May not be on TCA for Phase 3 of the study

  8. Vulvodynia Clinical Study: Phase 2 Dietary Intervention • Visit 1A- Subject completes informed consent and questionnaires • Visit 1B- Pelvic exam, blood and urine tests. Subject gets pain and symptom intensity questionnaires and diet diaries

  9. Vulvodynia Clinical Study: Phase 2 Dietary Intervention • Visit 2- Pain, symptom, diet data collected. Subjects randomly assigned to one of the two study diets • Visit 3-Depending on the response, subject may continue the diet for another 6 weeks or return in 2 weeks for entry into the Phase 3 of the study

  10. Vulvodynia Clinical Study: Phase 3 Goal To compare the response of subjects with vulvar pain to one of three interventions in a 12 week randomized study

  11. Vulvodynia Clinical Study: Phase 3 Three-arm treatment interventionstudy: • Tricyclic antidepressant (TCA) • Combination TCA and topical steroid • Self Management Intervention

  12. Vulvodynia Clinical Study:Phase 3 • Visit 1: After informed consent signed, subject randomized to one of three intervention groups • Visit 2 (Week 6): Review of diaries, medication, and side effects. Pelvic exam done, medication adjusted and diaries dispensed • Visit 3 (Week 12): A pelvic exam done and subject fills out several questionnaires

  13. Vulvodynia Clinical Study: Phase 3 Two Pharmacologic Interventions Two pharmacologic interventions: • Oral tricyclic antidepressant(amitriptyline)- 10mg at bedtime; may be increased to 20 mg daily • Topical corticosteroid (triamcinolone acetonide) applied in evening for first 4 weeks and Oral tricyclic antidepressant(amitriptyline) prescribed as above.

  14. Vulvodynia Clinical Study: Phase 3 Self Management Intervention • Subjects attend weekly meetings for twelve weeks • Meetings conducted by psychologist and physical therapist/nurse practitioner • Up to six subjects per group

  15. Vulvodynia Clinical Study: Phase 3 Self Management Intervention • Weekly meetings provide information about • Causes of vulvar pain • Role of stress • Helpful interventions taught • Other contributing factors • Relaxation, methods of stress reduction, self massage and sexual therapy techniques reviewed

  16. Vulvodynia: Conclusion • Vulvodynia is a chronic pain condition- prevalence underestimated in the female population • Diagnosis difficult due to poorly defined diagnostic criteria. • Other etiologies must be excluded before vulvodynia diagnosis

  17. Vulvodynia:For Further Information Contact: • UMDNJ-Robert Wood Johnson Medical School Women’s Health Institute email: whiinfo@umdnj.edu 732-235-7799 or 732-235-7965 • National Vulvodynia Association www.nva.org 301-299-0775 • Vulvar pain foundation www.vulvarpainfoundation.org 336-226-0704

More Related